The present disclosure generally relates to, inter alia, recombinant immune cells that have been engineered to express elevated levels of one or more glucose transporters, and particularly relate to engineered immune cells exhibiting increased glycolytic flux and/or enhanced effector functions. Also provided are methods for generating a population of engineered immune cells with enhanced effector function, pharmaceutical compositions the same, as well as methods and kits for the prevention and/or treatment of a health condition in subjects in need thereof.

Provided is an engineered immune cell. The expressions of at least one MHC related gene and at least one NK activating receptor binding molecule are suppressed or silenced, so as to suppress the killing of the engineered immune cell by NK cells. Also provided are a pharmaceutical composition comprising the engineered immune cell and use of the engineered immune cell in preparation of drugs for treatment of cancer, infection, or autoimmune diseases.

The invention relates to therapeutic compositions for allogeneic cellular therapy comprising TCR deficient T-cells, which are genetically engineered to express immune cell engagers, and methods related thereto.

Provided herein are D domain containing polypeptides that specifically bind targets of interest, as are nucleic acids encoding the D domain containing polypeptides, vectors containing the nucleic acids and host cells containing the nucleic acids and vectors. Also provided herein are methods of making and using the D domain containing polypeptides, nucleic acids, vectors and host cells, for example, but not limitefd to, in diagnostic and therapeutic applications. Also provided herein are multi-functional chimeric antigen receptor (CAR)-based compositions and Adapters and their use in methods of directing immune responses to target cells. In some embodiments, the methods include the use of a CAR expressing cell in combination with an Adapter. The Adapter confers the ability to modulate, alter, and/or direct CAR expressing cell-mediated immune response in vitro and in vivo.

The present invention relates to a polypeptide encoding a SLAMF7-binding chimeric antigen receptor (CAR), a polynucleotide encoding the SLAMF7-binding CAR polypeptide, a recombinant immune cell (preferably recombinant lymphocyte, more preferably recombinant T cell) comprising the polynucleotide, a method for producing recombinant immune cells and a pharmaceutical composition comprising recombinant immune cells. The recombinant immune cells and the pharmaceutical composition of the present invention may be used in methods for treating cancer in a patient thereby providing an improved treatment regimen. The inventors of the present application demonstrated that SLAMF7 CAR T-cells prepared by Sleeping Beauty gene transfer confer superior anti-myeloma efficacy in vivo compared to SLAMF7 CAR T-cells prepared by lentiviral gene transfer. Hence, SLAMF7 CAR T-cells that are prepared by virus-free SB gene transfer possess greater anti-myeloma efficacy and therapeutic potential, which leads to significantly improved clinical activity, and significantly improved clinical outcome.

The present invention provides an anti-human MSLN-specific antibody and an MSLN-targeting immune effector cell. Also provided is an MSLN-targeting chimeric antigen receptor modified T-cell prepared using the antibody and a use thereof.

The present invention is directed to chimeric antigen receptor (CAR) compositions and methods of their use in cancer and anti-viral immunotherapy. In particular, the CAR of the invention comprises a costimulatory signal (CSS) domain comprising herpes virus entry mediator protein (HVEM) or a functional fragment or variant thereof. CARs comprising such a HVEM CSS exhibit enhanced effector function.

The present invention relates to a universal-type efficient in-vitro amplification method for multiple times of clinical feedback of allogenic DNT cells. In the method of the present invention, the amount of a T cell activator is phased down in a continuous culture process without the need for additional interleukin-4 or AB serum.

Provided is a bispecific chimeric antigen receptor targeting CD19 and CD22, which comprises extracellular antigen binding domains of heavy-chain variable regions and light-chain variable regions of anti-CD19 and anti-CD22 antibodies. Further provided is a bispecific CAR-T cell targeting CD19 and CD22.

MAGE-A1 specific T cell receptors (TCRs) are provided. Accordingly, there is provided a TCR comprising a TCR α chain as set forth in SEQ ID NO: 1 having at least one mutation at an amino acid position selected from the group consisting of S189, G125, W55 and Y56; and/or a TCR β chain as set forth in SEQ ID NO: 2 having at least one mutation at an amino acid position selected from the group consisting of S32, S109 and T63, the TCR binds a MAGE-A1 peptide as set forth in SEQ ID NO: 25. Also provided are polynucleotides encoding the TCR and T cells expressing same and methods of use thereof.